Navigation Links
IDEV Announces Full Canadian Regulatory Approval for SUPERA VERITAS®
Date:4/14/2011

WEBSTER, Texas, April 14, 2011 /PRNewswire/ -- The Medical Devices Bureau of Health Canada has granted regulatory approval for the SUPERA VERITAS stent system for use in biliary and peripheral procedures.  IDEV's unique stent was previously available on a limited basis only, through the Special Access Program.

Christopher Owens, President and CEO of IDEV, commented, "With the full regulatory approval that has been granted we can immediately launch SUPERA VERITAS throughout Canada.  Based on early work with key physicians we anticipate rapid acceptance of our technology, and are pleased to offer this treatment option to physicians and their patients."

The approval clears the way for clinicians to utilize the SUPERA stent for patients with peripheral vascular disease (PVD) as well as those diagnosed with biliary strictures resulting from malignant neoplasms.  The proven mechanical characteristics of the SUPERA stent, including unmatched radial strength and fracture resistance, may result in improved clinical outcomes for these patients.

"Gaining full approval in Canada for SUPERA VERITAS is a significant development for the market," stated Vincent Oliva, M.D., Chief of Interventional Radiology at Centre Hospitalier de L'Universite de Montreal (CHUM).  "Based upon my experience, the highly differentiated features of the device, including its high radial strength and fracture resistance, and the clinical data presented showing exceptional outcomes, provide clinicians with a new and exciting option for treating PVD."

About IDEV Technologies, IncorporatedIDEV Technologies, Incorporated (IDEV) is an innovator and developer of next generation medical devices for use in interventional radiology, vascular surgery and cardiology.  IDEV's worldwide headquarters is located in Webster, Texas and its European headquarters is located in Beuningen, The Netherlands.  For more information please visit

SOURCE IDEV Technologies, Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 2015 BioElectronics Corporation (OTC Pink: BIEL), ... Therapy medical devices, announced today that its registry ... trial device has been published in the prominent ... http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than 5,000 chronic pain ... assessment.  Chronic pain is a ...
(Date:8/4/2015)... EDISON, N.J. , Aug. 4, 2015 /PRNewswire/ ... biopharmaceutical company focused on the development and commercialization ... Sapirstein , Chief Executive Officer, will present live ... DATE: Thursday, August 6, 2015 TIME: 12:15PM EDT ... will be a live, interactive online event where ...
(Date:8/4/2015)... 4, 2015  Ironshore Pharmaceuticals & Development, Inc. ... a company specializing in personalized medicine, to participate ... designed to evaluate the safety and efficacy of ... Attention-deficit/hyperactivity disorder (ADHD). This is Restore,s second clinical ... originally partnered with Ironshore in 2014 and continues ...
Breaking Medicine Technology:BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 3Restore Health Secures Another Clinical Trial with Ironshore Pharmaceuticals & Development 2
... voluntary recall of ALL lots of its Ketorolac Tromethamine Injection, USP ... NDC# 0517-0601-25 15 mg/mL ... This recall is in addition to the voluntary recall initiated on ... unexpired lots of Ketorolac Tromethamine Injection, USP, 30 mg/mL ...
... a next-generation oncology diagnostics company focused on improving ... closed a $21 million series A financing. ... and included Bessemer Venture Partners, Physic Ventures and ... ) , On-Q-ity is developing diagnostics to determine ...
Cached Medicine Technology:American Regent Expands Voluntary Recall to Include All Lots of Ketorolac Tromethamine Injection, USP 15 mg/mL; 1mL Single Dose Vials 2Cancer Diagnostics Company, On-Q-ity, Raises $21M in Series A Funding for the Development of Technologies to Personalize Cancer Therapy 2
(Date:8/4/2015)... ... August 05, 2015 , ... The Journal of Pain Research has ... corresponding author Professor Akiko Okifuji says “Both obesity and chronic pain are serious public ... say that one causes the other. Rather, there appear to be multiple factors that ...
(Date:8/4/2015)... ... August 04, 2015 , ... Atlantic Health System, one of the largest ... Fortune among the top five in their list of the 20 Best Workplaces in ... and Chilton Medical Centers, Goryeb Children’s Hospital and Atlantic Rehabilitation, is the highest-ranking company ...
(Date:8/4/2015)... ... August 04, 2015 , ... An article published July 27th by ... viable method for encouraging people to lose weight. Specifically the study compared control patients ... loss success, adding a financial incentive to the overall incentive of increased health. According ...
(Date:8/4/2015)... ... August 04, 2015 , ... PerceptiMed, Inc. ... Carmona, M.D., M.P.H., FACS, to its Board of Directors effective August 1, 2015. ... Dr. Carmona said. "I strongly believe in the mission of the company and ...
(Date:8/4/2015)... ... August 04, 2015 , ... One of the nation’s leading experts in chronic ... The Pain Antidote , which provides strategies for people who suffer from chronic ... Pain Treatment Program, wrote the book in conjunction with Katherine Ketcham, an author who ...
Breaking Medicine News(10 mins):Health News:The Association between Chronic Pain and Obesity published by Dove Medical Press 2Health News:Atlantic Health System Named a 'Best Workplace in Health Care' by Fortune, Great Place to Work® 2Health News:Atlantic Health System Named a 'Best Workplace in Health Care' by Fortune, Great Place to Work® 3Health News:Atlantic Health System Named a 'Best Workplace in Health Care' by Fortune, Great Place to Work® 4Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 2Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 3Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 2Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 3
... uncovered a vital new biological clue that could lead ... that currently kills more than 60 per cent of ... Brain Tumour Research Centre, working on behalf of the ... role of the WNT biological pathway in central nervous ...
... Cite Compliance with Regulatory Bodies as Top Driver ... to a Sparta Systems sponsored survey unveiled at ... quality-related headlines have had little impact on managers, ... efforts. Instead, the majority of respondents - ...
... Millions of Dollars in Paper, Printing and Mailing Costs ... Corporation (NYSE: EMC ), the world leader ... Cross (IBC), a leading health insurer, has been named ... an independent research and consulting firm focused on the ...
... pharmaceutical and bio-sciences owner operators helps greatly ... facility in a validated stateHUNTSVILLE, Ala., March ... engineering software provider, introduced today SmartPlant(R) for ... the cost of construction and qualification/commissioning activities ...
... CareBETHESDA, Md., March 18 The Cystic Fibrosis Foundation ... leadership in improving the quality of care for people ... Quality Assurance (NCQA).The outlook for people with CF continues ... by the Foundation. In the 1950s, few children with ...
... a Long-Acting Interferon and Ribavirin Will Earn Decision ... in 2012, According to a New Report from ... one of the world,s leading research and advisory ... surveyed gastroenterologists and hepatologists identify a therapy,s effect ...
Cached Medicine News:Health News:Study finds biological clue in brain tumor development 2Health News:Life Sciences Quality Managers Seek to Expand Compliance Initiatives Despite Economic Pressures 2Health News:Life Sciences Quality Managers Seek to Expand Compliance Initiatives Despite Economic Pressures 3Health News:EMC Document Sciences(R) xPression(R) Helps Independence Blue Cross Win Recognition as 2009 Celent Model Carrier 2Health News:Intergraph(R) Introduces SmartPlant(R) for Life Sciences 2Health News:Intergraph(R) Introduces SmartPlant(R) for Life Sciences 3Health News:Intergraph(R) Introduces SmartPlant(R) for Life Sciences 4Health News:Cystic Fibrosis Foundation to Receive Prestigious Health Care Award 2Health News:In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response 2Health News:In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response 3
Spacelabs offers an approach that allows your telemetry and step-down units to configure systems to meet their telemetry requirements. Our modular telemetry system data are integrated into the depart...
The Tele-Pro WEP-4200 Telemetry System is an 8-Patient Stand Alone System. Offering capabilities such as arrhythmia analysis, trends and full disclosure, the Tele-Pro is a system to help hospitals to...
ISI Ultra-Light Specialty Table offers the ultimate accessibility for surgeons, technicians and equipment during upper extremity surgeries....
Ademtechs Magnetic Beads are produced by encapsulation of a magnetic oil (patented technology). The magnetic content, uniform particle size, mono-dispersion properties, and the high surface area allo...
Medicine Products: